CAJ | 학술논문

目的：发现一系列新型选择性Mer酪氨酸激酶抑制剂（TKI）的母核结构，并依据其设计化合物。方法分别利用3个已发表的Mer TK及配体（化合物1、2和3）的复合晶体结构（PDB code：3TCP，4MHA和4M3Q），由ZINCPharmer来产生只包含配体核心区域的药效团模型，并对ZINC化合物库进行筛选。筛选结果经过分析、归类，得到新型母核结构，据其设计化合物，并利用分子对接技术对设计化合物进行初步评价。结果药效团筛选得到含有16253个化合物的数据集，归类为12种核心结构，它们可以和关键氨基酸形成相互作用的原子或基团。其中，化合物12将疏水脂肪链含于芳环中，结构变化较大，依据其设计了化合物16a～16d，分子对接发现16c评分最高，可作为进一步理性设计的基础。结论本研究通过基于药效团模型的虚拟筛选方法，发现了一系列选择性Mer TKI母核结构的替代物，它们保持了选择性抑制剂与靶点的关键作用，可应用于新化合物的设计中。同时，此方法也可用于其他靶标药物的发现中。
목적：발현일계렬신형선택성Mer락안산격매억제제（TKI）적모핵결구，병의거기설계화합물。방법분별이용3개이발표적Mer TK급배체（화합물1、2화3）적복합정체결구（PDB code：3TCP，4MHA화4M3Q），유ZINCPharmer래산생지포함배체핵심구역적약효단모형，병대ZINC화합물고진행사선。사선결과경과분석、귀류，득도신형모핵결구，거기설계화합물，병이용분자대접기술대설계화합물진행초보평개。결과약효단사선득도함유16253개화합물적수거집，귀류위12충핵심결구，타문가이화관건안기산형성상호작용적원자혹기단。기중，화합물12장소수지방련함우방배중，결구변화교대，의거기설계료화합물16a～16d，분자대접발현16c평분최고，가작위진일보이성설계적기출。결론본연구통과기우약효단모형적허의사선방법，발현료일계렬선택성Mer TKI모핵결구적체대물，타문보지료선택성억제제여파점적관건작용，가응용우신화합물적설계중。동시，차방법야가용우기타파표약물적발현중。
Objective To discover the core structures for a series of new selective Mer tyrosine kinase inhibitors(TKI ) and design their compounds accordingly. Method The pharmacophore of the core domain was respectively generated by cocrystal of Mer tyrosine kinase (Mer TK) and bound inhibitors 1 (UNC569), 2 and 3 (PDB code: 3TCP, 4MHA and 4M3Q) and used to proceed virtual screening with online platform ZINCPharmer. Core structures were obtained after analyzing and classifying the virtual screening results and used for new inhibitors design. Results Totally 16 253 compounds were screened out, and classified to 12 core structures. Based on structure 12, 16a-16d were designed and docked with Mer TK. Among them, 16c exhibited the lowest binding energy, which could be used for future drug design. Concludsion A series of core structures keeping critical interaction with Mer TK are discovered and can be used for the new selective Mer TKI design and development. The procedure can also be applied to other targets drug discovery.